Merck & Co., Inc.
MRK evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MRK—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MRK
Merck & Co., Inc. is a global biopharmaceutical company developing innovative medicines and vaccines across oncology, cardiometabolic, immunology, and infectious diseases, with a pipeline targeting over $70 billion in commercial opportunity by the mid-2030s.
Key risk: KEYTRUDA patent cliff
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 96 clinical trials · 51 catalysts for Merck & Co., Inc..
Merck & Co., Inc. is a global biopharmaceutical company developing innovative medicines and vaccines across oncology, cardiometabolic, immunology, and infectious diseases, with a pipeline targeting over $70 billion in commercial opportunity by the mid-2030s.
- Reported total revenue of $16,607.0M and net income of -$1,335.0M for the quarter ended 2026-06-30 [sec].
- Cash and equivalents of $6,891.0M, shareholders' equity of $52,606.0M, and total debt of $53,906.0M as of 2026-06-30 [sec].
- In 2025, the company announced positive results from 18 Phase 3 trials and initiated 21 new Phase 3 studies across multiple therapeutic areas [sec · filed 2026-04-08].
- The company sees opportunity to launch over 20 potential new growth drivers, almost all with blockbuster potential, based on its current pipeline [sec · filed 2026-04-08].
- Between 2018 and 2024, Merck invested more than $80 billion in R&D and $12 billion in manufacturing in the U.S. [sec · filed 2026-04-08].
What works
- Strong pipeline momentum with over 20 potential new growth drivers, almost all with blockbuster potential, and line of sight to over $70 billion in commercial opportunity by the mid-2030s [sec · filed 2026-04-08].
- Diversified therapeutic area expansion including immunology (tulisokibart), ophthalmology (MK-3000, MK-8748), and cardiometabolic (enlicitide) programs [sec · filed 2026-04-08].
- Substantial U.S. investment commitment of over $70 billion over several years to expand domestic manufacturing and R&D [sec · filed 2026-04-08].
- Proven commercial execution with KEYTRUDA reaching over $29 billion in sales in 2024 and successful launches like WINREVAIR [sec · filed 2025-04-09].
What to weigh
- Reported a net loss of $1,335.0M for the quarter ended 2026-06-30, indicating near-term profitability challenges [sec].
- Total debt of $53,906.0M exceeds shareholders' equity of $52,606.0M as of 2026-06-30, reflecting a leveraged balance sheet [sec].
- Preparing for the loss of exclusivity for KEYTRUDA, which generated over $29 billion in 2024 sales, creating a significant revenue gap risk [sec · filed 2026-04-08].
- Revenue growth was only 2% in 2025, suggesting limited near-term top-line expansion despite pipeline progress [sec · filed 2026-04-08].
From the filings
Quoted directly from source documents.
Merck announced positive results from 18 Phase 3 trials and initiated 21 new Phase 3 studies in 2025.
“In total, we announced positive results from 18 Phase 3 trials and initiated 21 new Phase 3 studies spanning cardiometabolic and respiratory, immunology, infectious diseases, oncology, and ophthalmology.”
SEC filings · April 8, 2026
Merck invested more than $80 billion in R&D and $12 billion in manufacturing in the U.S. between 2018 and 2024.
“In the U.S. between 2018 and 2024, we invested more than $80 billion in R&D and $12 billion in manufacturing.”
SEC filings · April 8, 2026
KEYTRUDA sales reached over $29 billion in 2024, growing 22%.
“In oncology, KEYTRUDA grew by 22% (1) , reaching over $29 billion in sales, driven by continued strong global demand from metastatic disease, as well as an increased global uptake in earlier-stage cancers.”
SEC filings · April 9, 2025
Catalyst timeline
- 2027-03-01 · Phase3_Topline · rosuvastatin — Phase 3 Topline — Topline results from a Phase 3 study evaluating efficacy of rosuvastatin in a new indication.
- 2027-06-24 · Phase3_Topline — Phase 3 Topline — Topline results from a Phase 3 randomized, double-blind, placebo-controlled efficacy study.
- 2027-07-22 · Phase3_Topline — Phase 3 Topline — Topline results from a Phase 3 active-controlled, double-blind efficacy and safety study.
- 2027-08-03 · Phase3_Topline — Phase 3 Topline — Topline results from an open-label, individual dose titration study evaluating safety and pharmacokinetics.
- 2027-09-24 · Phase3_Topline · zilovertamab — Phase 3 Topline — Topline results from a Phase 2/3 study of zilovertamab vedotin in an active-controlled setting.
- 2027-10-18 · Phase3_Topline — Phase 3 Topline — Topline results from a Phase 3 randomized, active-controlled, double-blind efficacy study.
- 2028-03-24 · Phase3_Topline — Phase 3 Topline — Topline results from a Phase 3 randomized, double-blind, active-comparator-controlled efficacy study.
- 2028-06-15 · Phase3_Topline — Phase 3 Topline — Topline results from a Phase 3 randomized, active-controlled, open-label, multicenter efficacy study.
Risks & what to watch (4)›
Key risks
- KEYTRUDA patent cliff — Loss of exclusivity for KEYTRUDA, which generated over $29B in 2024 sales, creates a major revenue gap [sec · filed 2026-04-08].
- High debt leverage — Total debt of $53.9B exceeds equity of $52.6B as of 2026-06-30, increasing financial risk [sec].
- Near-term net loss — Reported net loss of $1.3B for Q2 2026, indicating profitability pressure [sec].
- Pipeline execution risk — Dependence on over 20 early-stage pipeline assets to replace KEYTRUDA revenue carries clinical and regulatory uncertainty [sec · filed 2026-04-08].
What to watch
- Phase 3 topline results for enlicitide (oral PCSK9 inhibitor) and other cardiometabolic programs [sec · filed 2026-04-08].
- Progress of tulisokibart in Phase 2b trials for additional immunology indications [sec · filed 2026-04-08].
- Regulatory decisions and uptake of KEYTRUDA subcutaneous formulation (KEYTRUDA QLEX) [sec · filed 2026-04-08].
- Upcoming Phase 3 readouts for zilovertamab vedotin and other oncology assets through 2027-2028 [catalyst timeline].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run Merck & Co., Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Merck & Co., Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Profitable (positive operating cash flow)
D/E 2.10 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
51 upcoming, next in ~183d
0 buys · 17 sells (180d)
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
3,763
Total value held
$241.59B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 321,975,248 | $38.73B |
| blackrock, inc. | 225,926,330 | $27.18B |
| state street corp | 119,325,673 | $14.45B |
| wellington management group llp | 84,314,971 | $10.14B |
| vanguard portfolio management llc | 67,304,305 | $8.10B |
| geode capital management, llc | 59,558,154 | $7.14B |
| charles schwab investment management inc | 49,765,225 | $5.99B |
| morgan stanley | 47,632,487 | $5.73B |
| fmr llc | 44,516,010 | $5.35B |
| bank of america corp /de/ | 30,774,221 | $3.70B |
Showing top 10 of 3,763 institutional holders of Merck & Co., Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 1.1%
- Days to cover
- 2.8
- Shares short
- 26,205,868
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MRK short interestGovernance
Frequently asked questions
What is the AI investment thesis for Merck & Co., Inc.?
Merck & Co., Inc. is a global biopharmaceutical company developing innovative medicines and vaccines across oncology, cardiometabolic, immunology, and infectious diseases, with a pipeline targeting over $70 billion in commercial opportunity by the mid-2030s.
What is Merck & Co., Inc.'s next catalyst?
Merck & Co., Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy " — expected March 1, 2027.
Who is the CEO of Merck & Co., Inc.?
Mr. Robert M. Davis J.D. is the chief executive officer of Merck & Co., Inc. (MRK).
Where is Merck & Co., Inc. headquartered?
Merck & Co., Inc. (MRK) is headquartered in Rahway, NJ, United States.
What therapeutic areas does Merck & Co., Inc. focus on?
Merck & Co., Inc. develops therapies across Oncology, Rare Disease, Immunology, Ophthalmology, Cardiovascular, Infectious Disease, Metabolic, Respiratory, Dermatology, Hematology, Nephrology, Musculoskeletal, Gastroenterology, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.